66
Chapter 20 Care of Patients with Arthritis and Other Connective Tissue Diseases

Chapter 20

  • Upload
    pia

  • View
    32

  • Download
    0

Embed Size (px)

DESCRIPTION

Chapter 20. Care of Patients with Arthritis and Other Connective Tissue Diseases. Rheumatology. Connective tissue disease (CTD) is a major focus of rheumatology. Rheumatic disease is any disease or condition involving the musculoskeletal system. - PowerPoint PPT Presentation

Citation preview

Page 1: Chapter 20

Chapter 20

Care of Patients with Arthritis and Other Connective Tissue

Diseases

Page 2: Chapter 20

Rheumatology

• Connective tissue disease (CTD) is a major focus of rheumatology.

• Rheumatic disease is any disease or condition involving the musculoskeletal system.

• Arthritis means inflammation of one or more joints.

Page 3: Chapter 20

Rheumatology (Cont’d)

• Noninflammatory arthritis (osteoarthritis) is not systemic. OA is not an autoimmune disease.

• Inflammatory arthritis:– Rheumatoid arthritis– Systemic lupus erythematosus– Autoimmune disease– Connective tissue disease that is inflammatory

Page 4: Chapter 20

Osteoarthritis

• Most common type of arthritis• Joint pain and loss of function characterized

by progressive deterioration and loss of cartilage in the joints

• Osteophytes• Synovitis• Subluxation

Page 5: Chapter 20

Joint Changes in Degenerative Joint Disease

Page 6: Chapter 20

Collaborative Management

• History• Physical assessment and clinical

manifestations:– Joint involvement– Heberden's nodes– Bouchard’s nodes– Joint effusions– Atrophy of skeletal muscle

Page 7: Chapter 20

Heberden’s Nodes

Page 8: Chapter 20

Ballottement

Page 9: Chapter 20

Assessments

• Psychosocial• Laboratory assessment of erythrocyte

sedimentation rate and C-reactive protein (may be slightly elevated)

• Radiographic assessment• Other diagnostic assessments:

– MR imaging– CT studies

Page 10: Chapter 20

Chronic Pain: Nonsurgical Management

• Analgesics• Rest• Positioning• Thermal modalities• Weight control• Integrative therapies

Page 11: Chapter 20

Chronic Pain: Surgical Management

• Total joint arthroplasty (TJA)• Total joint replacement (TJR)• Arthroscopy• Osteotomy

Page 12: Chapter 20

Total Hip Arthroplasty

• Preoperative care• Operative procedures• Postoperative care:

– Prevention of dislocation, infection, and thromboembolic complications

– Assessment of bleeding– Management of anemia

Page 13: Chapter 20

Hip Flexion After Total Hip Replacement

Page 14: Chapter 20

Prevention of Complications

• Assessment for neurovascular compromise• Management of pain• Progression of activity• Promotion of self-care

Page 15: Chapter 20

Total Knee Arthroplasty

• Preoperative care• Operative procedures• Postoperative care:

– Continuous passive motion machine– Hot/ice device– Pain management– Neurovascular assessment

Page 16: Chapter 20

Continuous Passive Motion Machine

Page 17: Chapter 20

Rheumatoid Arthritis

• One of the most common connective tissue diseases and the most destructive to the joints

• Chronic, progressive, systemic inflammatory autoimmune disease affecting primarily the synovial joints

• Autoantibodies (rheumatoid factors) formed that attack healthy tissue, especially synovium, causing inflammation

• Affects synovial tissue of any organ or body system

Page 18: Chapter 20

RA Pathology

Page 19: Chapter 20

RA—Collaborative Management

• Assessment• Physical assessment and clinical

manifestations:– Early disease manifestations—joint stiffness,

swelling, pain, fatigue, and generalized weakness and morning stiffness

– Late disease manifestations—as the disease worsens, the joints become progressively inflamed and quite painful

Page 20: Chapter 20

RA Joint Involvement

Page 21: Chapter 20

RA Systemic Complications

• Weight loss, fever, and extreme fatigue• Exacerbations• Subcutaneous nodules• Pulmonary complications• Vasculitis• Periungual lesions• Paresthesias• Cardiac complications

Page 22: Chapter 20

RA—Assessments

• Psychosocial assessment• Laboratory assessment—rheumatoid factor,

antinuclear antibody titer, erythrocyte sedimentation rate, serum complement, serum protein electrophoresis, serum immunoglobulins

• Other diagnostic assessments—x-ray, CT, arthrocentesis, bone scan

Page 23: Chapter 20

RA—Drug Therapy

• Disease-modifying antirheumatic drugs• NSAIDs• Biologic response modifiers• Other drugs:

– Glucocorticoids– Immunosuppressive agents– Gold therapy– Analgesic drugs

Page 24: Chapter 20

RA—Nonpharmacologic Interventions

• Adequate rest• Proper positioning• Ice and heat applications• Plasmapheresis• Gene therapy• Complementary and alternative therapies• Promotion of self-care

Page 25: Chapter 20

RA—Nonpharmacologic Interventions (Cont’d)

• Management of fatigue• Enhancement of body image• Community-based care:

– Home care management– Health teaching– Health care resources

Page 26: Chapter 20

Lupus Erythematosus

• Chronic, progressive, inflammatory connective tissue disorder that can cause major body organs and systems to fail.

• Characterized by spontaneous remissions and exacerbations.

• Autoimmune process.• Autoimmune complexes tend to be attracted to the

glomeruli of the kidneys.• Many patients with SLE have some degree of

kidney involvement.

Page 27: Chapter 20

Lupus Erythematosus—Clinical Manifestations

• Skin involvement• Polyarthritis• Osteonecrosis• Muscle atrophy• Fever and fatigue

Page 28: Chapter 20

Characteristic “Butterfly” Rash of Systemic Lupus

Erythematosus

Page 29: Chapter 20

LE—Clinical Manifestations

• Renal involvement• Pleural effusions• Pericarditis• Raynaud’s phenomenon• Neurologic manifestation• Serositis

Page 30: Chapter 20

Assessments for Lupus

• Psychosocial results can be devastating.• Laboratory:

– Skin biopsy (only significant test to confirm diagnosis)

– Immunologic-based laboratory tests– Complete blood count– Body system function assessment

Page 31: Chapter 20

SLE—Drug Therapy

• Topical drugs• Plaquenil• Tylenol or NSAIDs• Chronic steroid therapy• Immunosuppressive agents

Page 32: Chapter 20

Scleroderma (Systemic Sclerosis)

• Chronic, inflammatory, autoimmune connective tissue disease

• Not always progressive• Hardening of the skin

Page 33: Chapter 20

Scleroderma

Page 34: Chapter 20

CREST Syndrome

• C—calcinosis• R—Raynaud’s phenomenon• E—esophageal dysmotility• S—sclerodactyly• T—telangiectasia

Page 35: Chapter 20

Scleroderma—Clinical Manifestations

• Arthralgia• GI tract• Cardiovascular system• Pulmonary system• Renal system

Page 36: Chapter 20

Scleroderma—Interventions

• Drug therapy• Identify early organ involvement• Skin protective measures• Comfort• GI manifestation• Mobility

Page 37: Chapter 20

Gout

• Also called gouty arthritis, a systemic disease in which urate crystals deposit in the joints and other body tissues, causing inflammation

• Primary gout• Secondary gout—hyperuricemia

Page 38: Chapter 20

Gout—Interventions

• Drug therapy• Nutritional therapy

Page 39: Chapter 20

Other Connective Tissue Diseases

• Polymyositis• Systemic necrotizing vasculitis• Polymyalgia rheumatica and temporal

arteritis• Ankylosing spondylitis• Reiter’s syndrome• Marfan syndrome• Infectious arthritis

Page 40: Chapter 20

Lyme Disease

• Reportable systemic infectious disease caused by the spirochete Borrelia burgdorferi, resulting from the bite of an infected deer tick.

• Stages I and II.• If not diagnosed and treated in early stages,

chronic complications such as arthralgias, fatigue, and memory and thinking problems can result.

• For some patients, the first and only sign of Lyme disease is arthritis.

Page 41: Chapter 20

Lyme Disease Rash

Page 42: Chapter 20

Fibromyalgia Syndrome

• Chronic pain syndrome, not an inflammatory disease

Page 43: Chapter 20

Chronic Fatigue Syndromes

• Chronic illness in which patients have severe fatigue for 6 months or longer, usually following flu-like symptoms

• Sore throat; substantial impairment in short-term memory or concentration; tender lymph nodes; muscle pain; multiple joint pain with redness or swelling; headaches of a new type, pattern, or severity; unrefreshing sleep; and postexertional malaise lasting more than 24 hours

Page 44: Chapter 20

Chapter 22

Care of Patients with Immune Function Excess: Hypersensitivity

(Allergy) and Autoimmunity

Page 45: Chapter 20

Hypersensitivities/Allergies

• Increased or excessive response to the presence of an antigen to which the patient has been exposed

• Degree of reaction ranging from uncomfortable to life threatening

Page 46: Chapter 20

Type I: Rapid Hypersensitivity Reactions

• Also called atopic allergy, this is the most common type of hypersensitivity.

• Some reactions occur just in the areas exposed to the antigen.

Page 47: Chapter 20

Type I: Rapid Hypersensitivity Reactions (Cont’d)

• Allergens can be contacted in these ways:– Inhaled (plant pollens, fungal spores, animal

dander, house dust, grass, ragweed)– Ingested (foods, food additives, drugs)– Injected (bee venom, drugs, biologic

substances)

Page 48: Chapter 20

Type I: Rapid Hypersensitivity Reactions (Cont’d)

– Contacted (pollens, foods, environmental proteins)

• Other reactions may involve all blood vessels and bronchiolar smooth muscle, causing widespread blood vessel dilation, decreased cardiac output, and bronchoconstriction, which is known as anaphylaxis

Page 49: Chapter 20

Allergic Rhinitis

Page 50: Chapter 20

Patient-Centered Collaborative Care

• History• Laboratory assessment—increased

eosinophils, immunoglobulin E (IgE), RAST

• Allergy testing– Patient preparation– Procedure– Follow-up care

• Oral food challenges

Page 51: Chapter 20

Interventions

• Avoidance therapy:– Environmental changes:

• Air-conditioning and air-cleaning units• Cloth drapes• Upholstered furniture• Carpeting

– Pet-induced allergies

Page 52: Chapter 20

Drug Therapy

• Decongestants• Antihistamines• Corticosteroids• Mast cell stabilizers• Leukotriene antagonists• Complementary and alternative therapy• Desensitization therapy

Page 53: Chapter 20

Anaphylaxis

• First feelings of uneasiness, apprehension, weakness, and impending doom.

• Pruritus and urticaria.• Erythema and sometimes angioedema of the eyes,

lips, or tongue.

Page 54: Chapter 20

Anaphylaxis (Cont’d)

• Histamine causes capillary leak, bronchoconstriction, mucosal edema, and excess mucus secretion.

• Congestion, rhinorrhea, dyspnea, and increasing respiratory distress with audible wheezing result.

• Anaphylaxis can be fatal.

Page 55: Chapter 20

Interventions

• First assess respiratory function; an airway must be established.

• CPR may be needed.• Epinephrine (1:1000) 0.3 to 0.5 mL subcutaneous

is given as soon as symptoms appear.• Antihistamines treat angioedema and urticaria.• Oxygen. • Treat bronchospasm.• IV fluids.

Page 56: Chapter 20

Type II: Cytotoxic Reactions

• The body makes special autoantibodies directed against self cells that have some form of foreign protein attached to them.

• Clinical examples include hemolytic anemias, thrombocytopenic purpura, hemolytic transfusion reactions, Goodpasture’s syndrome, and drug-induced hemolytic anemia.

Page 57: Chapter 20

Antibody-Antigen Complexes

Page 58: Chapter 20

Type III: Immune Complex Reactions

• Excess antigens cause immune complexes to form in the blood. These circulating complexes usually lodge in small blood vessels.

• Usual sites include the kidneys, skin, joints, and small blood vessels.

Page 59: Chapter 20

Type III: Immune Complex Reactions (Cont’d)

• Deposited complexes trigger inflammation, resulting in tissue or vessel damage.

• Rheumatoid arthritis, systemic lupus erythematosus, and serum sickness occur.

Page 60: Chapter 20

Immune Complex in a Type III Hypersensitivity Reaction

Page 61: Chapter 20

Type IV: Delayed Hypersensitivity Reactions

• In a type IV reaction, the reactive cell is the T-lymphocyte (T-cell).

• Antibodies and complement are not involved.

• Local collection of lymphocytes and macrophages causes edema, induration, ischemia, and tissue damage at the site.

Page 62: Chapter 20

Type IV: Delayed Hypersensitivity Reactions

(Cont’d)• Other examples include positive purified

protein derivative, contact dermatitis, poison ivy skin rashes, insect stings, tissue transplant rejection, and sarcoidosis.

Page 63: Chapter 20

Type V: Stimulatory Reaction

• Excess stimulation of a normal cell surface receptor by an autoantibody, resulting in a continuous “turned-on” state for the cell.

• Graves’ disease.

Page 64: Chapter 20

Autoimmunity

• Autoimmunity is the process whereby a person develops an inappropriate immune response.

• Antibodies and/or lymphocytes are directed against healthy normal cells and tissues.

• For unknown reasons, the immune system fails to recognize certain body cells or tissues as self and triggers immune reactions.

Page 65: Chapter 20

Sjögren’s Syndrome

• Group of problems that often appear with other autoimmune disorders

• Dry eyes, dry mucous membranes of the nose and mouth (xerostomia), and vaginal dryness

• Insufficient tears causing inflammation and ulceration of the cornea

• No cure; intensity and progression can be slowed by suppressing immune and inflammatory responses

Page 66: Chapter 20

Goodpasture’s Syndrome

• Autoimmune disorder in which autoantibodies are made against the glomerular basement membrane and neutrophils

• Lungs and kidneys• Shortness of breath, hemoptysis, decreased

urine output, weight gain, edema, hypertension, and tachycardia

• Treatment—high-dose corticosteroids